Skip to main content
Figure 1 | BMC Pharmacology and Toxicology

Figure 1

From: Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG®) in patients with mycosis fungoides: an open-label trial

Figure 1

Interferon concentrations in serum. Legend: Data correspond to 12 patients with mycosis fungoides who received 23 × 106 IU of HeberPAG®. Each point represents the average and standard deviation of (a) IFN alpha-2b and (b) IFN gamma levels, both measured by EIA

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us